Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting

ASGCT presentation will include positive data from herpes simplex virus-1 keratitis program, EBT-104, as well as an overview of a next-generation AAV delivery vector

Excision BioTherapeutics Announces Oral Presentation Highlighting Positive Data from its HBV Program, EBT-107, at the Upcoming ASGCT 2024 Annual Meeting

Oral presentation to highlight proof-of-concept efficacy in reducing HBV biomarkers in serum and intrahepatic HBV in vivo

Excision BioTherapeutics Announces Oral Presentation of Preclinical HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24, 2024

Treatment with EBT-104 resulted in over 90% reduction in viral shedding in HSV-1 Keratitis model